Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
For our 17th video in the GRACE Spanish Lung Cancer Library, 
Dr. Brian Hunis, Medical Director, Head and Neck Cancer Program, Memorial Cancer Institute, Miami, Florida, joined GRACE to discuss the basics of Lung Cancer for Spanish-speaking patients and caregivers. In this video Dr. Hunis speaks about first line therapy for non-small cell lung cancer patients that have anaplastic lymphoma kinase (ALK) positive.
TRANSCRIPTS - Spanish and English
Terapia de primera línea para pacientes con cáncer pulmonar de células no pequeñas que presentan la cinasa de linfoma anaplásico (CLA) positiva.
En los pacientes en los cuales uno describe que el adenocarcinoma de pulmón de células no pequeñas tiene la translocación del gen ALK, hay terapia dirigida que atacan exclusivamente a las células que expresan esa mutación. Por lo cual los efectos adversos, la toxicidad y las respuestas son muchísimo mejores.
La primera terapia para pacientes con translocación en ALK que se ha usado en el mundo es con crisotinib. Crisotinib es una píldora que se toma diariamente, es bien tolerada y con efectos muy positivos.
First line therapy for non-small cell lung cancer patients that have the anaplastic lymphoma kinase positive.
In patients that have adenocarcinoma of non-small cells and also have the ALK gene translocation, there is a targeted treatment that only attacks the cell that express this mutation. So, the side effects, toxicity and the response are better.
The first therapy for patients with the ALK translocation that has been used in the world is with crisotinib. Crisotinib is a pill that is taken daily, is well tolerated and with very positive effects.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.
Glad to help. FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/
Hope to see...